Hossein Pourghadamyari

Dr. Hossein Pourghadamyari


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Talanta
Verified
Journal Article
Closed access
EHElyas Hosseinzadeh
Elyas Hosseinzadeh
HRHadi Ravan
Hadi Ravan
AMAbbas Mohammadi
Abbas Mohammadi
HPHossein Pourghadamyari
Hossein Pourghadamyari

18 June 2025 in Journal of Health, Population and Nutrition
Verified
Journal Article
Open access
PDF file
ZSZahra Sarkoohi
Zahra Sarkoohi
MBMohammad-Mahdi Bastan
Mohammad-Mahdi Bastan
MGMohammad Amin Khajuei Gharaei
Mohammad Amin Khajuei Gharaei
MIMahsa Iranmanesh
Mahsa Iranmanesh
AAArya Adinepour
Arya Adinepour
SNSeyed Aria Nejadghaderi
Seyed Aria Nejadghaderi
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a condition marked by excess liver fat, ranging from simple steatosis to non-alcoholic steatohepatitis. Updated reports on the epidemiology of MASLD in the Middle East and North Africa (MENA) region are needed. This study aimed to report the trends in the MASLD burden in the MENA region from 1990 to 2021, as well as age and sex patterns and their association with the sociodemographic index (SDI). Data on the incidence, prevalence, disability-adjusted life years (DALYs), and mortality of MASLD in 21 countries within the MENA region from 1990 to 2021 were extracted from the GBD 2021 study. The relationship with the SDI and the burden attributable to risk factors, such as high fasting plasma glucose and smoking, were examined. Between 1990 and 2021, the MENA region experienced a 13.8% increase in the age-standardized incidence rate, reaching 1,037.6 per 100,000 population. The age-standardized prevalence saw a rise of 26.4%. Women experienced a higher increase in incidence than men. The highest rates of DALYs were observed among older adults. Countries with a high SDI faced a greater disease burden. High fasting plasma glucose accounted for the largest burden of MASLD. The study found that the incidence and prevalence of MASLD in the MENA region increased significantly from 1990 to 2021, especially in areas with high SDI. High fasting plasma glucose was the most significant attributable risk factor, highlighting the need for metabolic interventions. Not applicable.

2 June 2023 in Journal of Trace Elements in Medicine and Biology
Verified
Journal Article
Closed access
ZMZeinab Mokhtari
Zeinab Mokhtari
ESEffat Seyedhashemi
Effat Seyedhashemi
MEMaryam Eftekhari
Maryam Eftekhari
SGShiva Ghasemi
Shiva Ghasemi
ASAkram Sabouri
Akram Sabouri
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar

1 January 2024
Verified
Journal Article
Open access
RBRosita Azar Bahadori
Rosita Azar Bahadori
DSDina Shabani
Dina Shabani
EAElham Arjmandrad
Elham Arjmandrad
MKMahsa Kazerani
Mahsa Kazerani
MRMina Rohani
Mina Rohani
MZMohammad Ali Zaemi
Mohammad Ali Zaemi
Coronary artery diseases (CAD) represent a significant global health concern and are recognized as a primary contributor to mortality on a worldwide scale. Early diagnosis of CAD is one of promising goal to manage this disorder. Recent investigations have highlighted the pivotal involvement of microRNAs (miRNAs) in diverse health conditions, notably CAD. The principal objective of this investigation was to identify appropriate miRNAs that could be employed for the early detection of CAD. In the present study, we analyzed dataset of CAD (GSE113079) and 100 differentially expressed mRNAs (DEmRNAs) were detected. The miRNAs that have a significant interaction with DEmRNAs were chosen. By computational prediction method, 5 miRNAs (miR-106b-5p, miR-20a-3p, miR-17-3p, miR-146a-5p, and miR-155-3p) were selected. Finally, we assessed the anticipated expression levels of microRNAs in CAD patients and healthy control groups. Our findings revealed a statistically significant elevation solely in the expression level of miR-106b-5p within the CAD group when compared to the control group (p>0.001). Our study demonstrated an elevation in the expression of miR-106b-5p in individuals diagnosed with CAD. This microRNA may be used as a diagnostic biomarker in patients with CAD. However, further investigations are needed to confirm these results.

1 September 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
SMSaeedeh Mosallanejad
Saeedeh Mosallanejad
MMMehdi Mahmoodi
Mehdi Mahmoodi
HTHadi Tavakkoli
Hadi Tavakkoli
AKAhmad Khosravi
Ahmad Khosravi
ESEhsan Salarkia
Ehsan Salarkia
HPHossein Pourghadamyari
Hossein Pourghadamyari
The present investigation was conducted to evaluate the vascular-toxicity of empagliflozin (EMP) in embryonic vasculature. Firstly, the vascular-toxicity of the drug as well as its interaction with apoptotic regulator proteins was predicted via in silico approach. In the next step, the apoptotic-signaling pathway in embryonic vasculature was evaluated using a chick’s YSM model. In silico simulation confirmed vascular-toxicity of EMP. There was also an accurate affinity between EMP, Bax and Bcl-2 (−7.9 kcal/mol). Molecular dynamics assay revealed complex stability in the human body conditions. Furthermore, EMP is suggested to alter Bcl-2 more than BAX. Morphometric quantification of the vessels showed that the apoptotic activity of EMP in embryonic vasculature was related to a marked reduction in vessel area, vessel diameter and mean capillary area. Based on the qPCR and immunohistochemistry assays, enhanced expression level of BAX and reduced expression level of Bcl-2 confirmed apoptotic responses in the vessels of the YSM. We observed that induction of an apoptotic signal can cause the embryonic defect of the vascular system following EMP treatment. The acquired data also raised suspicions that alteration in apoptotic genes and proteins in the vasculature are two critical pathways in vascular-toxicity of EMP.

9 April 2024 in Research Square
Verified
Preprint
Open access
PDF file
ASAli Samareh
Ali Samareh
HPHossein Pourghadamyari
Hossein Pourghadamyari
MNMohammad Hadi Nemtollahi
Mohammad Hadi Nemtollahi
HEHossein Ali Ebrahimi
Hossein Ali Ebrahimi
MNMohammad Erfan Norouzmahani
Mohammad Erfan Norouzmahani
GAG.R. Asadi
G.R. Asadi
Background Parkinson's disease (PD) is a complex disorder that arises from genetic and environmental factors. The current investigation endeavors to investigate the role of exposure to organochlorines (OCPs) and organophosphate pesticides (OPPs), recognized as the main environmental elements, in the genesis of PD. Methods In this case-control study, 29 PD patients and 51 healthy subjects (controls) were involved. Gas chromatography (GC) was performed to measure the serum levels of organochlorine chemicals (2,4-DDT, 4,4-DDT, 2,4-DDE, 4,4-DDE, α-HCH, β-HCH, and γ-HCH). Furthermore, acetylcholinesterase (AChE) activity, arylesterase activity of paraoxonase-1 (PON-1), and several oxidative stress (OS) markers were assessed. Results The levels of OCPs in the PD patients were significantly higher than in the control subjects. In addition, AChE activity, arylesterase activity of PON-1, catalase (CAT) activity, and superoxide dismutase 3 (SOD3) activity in PD patients were significantly less than controls. Although the levels of carbonyl protein (CP), total antioxidant capacity (TAC), malondialdehyde (MDA), and nitric oxide (NO) in PD patients were higher than the controls. Conclusion The findings of this investigation have indicated that OCPs and OPPs exposure could contribute to the development of Parkinson's disease. This potential linkage could either be established through the direct impact of these pesticides on the nervous system, leading to neurotoxicity, or via an indirect route through the triggering of OS.